Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CISD2 | Q8N5K1 | 12/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239048 | 0.87 | ALDH1A1 (0.78) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3496735 | 0.86 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3498311 | 0.85 | MAPT (0.77) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL8054398 | 0.83 | GRM6 (0.59) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30216424 | 0.80 | ALDH1A1 (0.71) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9400300 | 0.80 | ALDH1A1 (0.71) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12082955 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10633454 | 0.77 | GRM6 (0.60) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6030914 | 0.74 | MAPT (0.61) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1063435 | 0.74 | KDM4E (0.60) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332276-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | UNIV PENNSYLVANIA (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4529460-A1 | <SMALLCAPS/>? ? ?MOLLUSCUM CONTAGIOSUM? ? ? ? ?INHIBITORS OFINFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2025-04-02 | — | — | EP | disclosed |
| CN-119486732-A | Molluscum contagiosum infection inhibitor and method of use thereof | 宾夕法尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| CN-118541359-A | Inhibitors of molluscum contagiosum infection and methods of use thereof | 宾夕法尼亚大学董事会 | 2024-08-23 | — | — | CN | disclosed |
| EP-4408833-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023230472-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023049919-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-03-30 | — | — | WO | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332276-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | TBK1, EIF2AK2, ITCH | KDM4E 1172/4885ALDH1A1 3850/4885MAPT 1645/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | KDM4E 4164/4885ALDH1A1 1930/4885MAPT 9/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | KDM4E 4164/4885ALDH1A1 1930/4885MAPT 9/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | KDM4E 4164/4885ALDH1A1 1930/4885MAPT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.